Study to Evaluate the Safety and Efficacy of the GGTA1 KO Thymokidney in Patients With ESRD
NCT07224763
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to evaluate the safety and efficacy of the GGTA1 KO Thymokidney in patients with end-stage renal disease (ESRD) who are either not eligible for conventional allogeneic kidney transplantation (Group 1) or are on an Organ Procurement and Transplantation Network (OPTN) kidney transplant waitlist, but are more likely to die or go untransplanted within 5 years than receive a kidney transplant (Group 2).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- ESRD (End-Stage Renal Disease)
- Kidney Transplantation
- Xenotransplantation
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 40 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- United Therapeutics
- Last updated on ClinicalTrials.gov
- September 9, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
New York · 1
- New York University Langone Health · New York, NY
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.